Overview

Inspire Medical Systems is a publicly-listed medical device company (NYSE: INSP) developing implantable hypoglossal nerve stimulation for obstructive sleep apnea. The company was founded in 2007 and is headquartered at 5500 Wayzata Boulevard in Golden Valley, Minnesota. Tim Herbert serves as Chair, President, and CEO. Inspire went public on the NYSE in May 2018 at an IPO price of $16 per share.

The Inspire device

The Inspire system is an implantable neurostimulator that delivers timed electrical pulses to the hypoglossal nerve during sleep to keep the airway open. The device is the only FDA-approved implantable therapy for moderate-to-severe obstructive sleep apnea in patients who cannot tolerate continuous positive airway pressure (CPAP) treatment. The procedure typically involves implanting the pulse generator in the chest with a lead routed to the hypoglossal nerve in the neck.

2026 commercial challenges

In May 2026, Inspire cut its 2026 revenue guidance from $950 million-$1 billion to $825-875 million, a projected decline of 4-10% versus 2025 and a roughly $125 million reduction at the midpoint. The cut was driven primarily by the CMS WISeR (Wasteful and Inappropriate Service Reduction) prior-authorization programme that took effect 1 January 2026 and placed the Inspire procedure on its services list, combined with a CPT code transition (the procedure is moving to code 64582 with a -52 modifier) that created billing uncertainty. Q1 2026 alone saw approximately $20 million of revenue impact from these factors. Bank of America analyst Travis Steed downgraded the stock from Neutral to Underperform in the same week as the guidance cut.

Additional headwinds

Beyond CMS WISeR, Inspire’s 2026 outlook is also affected by three further factors: GLP-1 medication competition (Ozempic and Wegovy reduce weight-related sleep apnea symptoms in some patients), salesforce disruption, and increased competition from devices and alternative therapies.

Strategic position

Inspire sits on the open-loop end of the neuromodulation market and is one of the most visible companies caught in the CMS WISeR bifurcation pattern. The structural contrast with closed-loop peer NeuroPace (off the WISeR services list, +20% revenue growth, raised guidance in the same window) has become the case study for how a single CMS rule cycle can redistribute the commercial trajectory of devices in the same neuromodulation category based purely on which procedure codes the WISeR list includes.